Skip to main content

Table 6 Baseline characteristics and VAP episode description in the statin previous users according to the 30-day mortality

From: Impact of prior statin therapy on the outcome of patients with suspected ventilator-associated pneumonia: an observational study

  Survivors Nonsurvivors P
(n = 60) (n = 33)
Age (years) 62.5 (27.0-81.0) 74.0 (50.0-90.0) <0.01
SAPS II (points) 48.0 (18.0-109.0) 57.0 (30.0-86.0) 0.01
Gender, male (n (%)) 50 (83.3) 30 (90.9) 0.31
Hospitalization prior to ICU admission (n (%)) 41 (68.3) 23 (69.7) 0.89
Underlying disease(s) (n (%))    
 Chronic renal failure 5 (8.5) 5 (15.1) 0.32
 Cardiac chronic disease 38 (64.4) 27 (81.8) 0.08
 Diabetes mellitus 19 (32.2) 10 (30.3) 0.99
 COPD 15 (25.0) 9 (27.3) 0.81
 Cirrhosis 1 (1.7) 1 (3.3) 0.67
 Immunosuppression 4 (6.8) 0 (0.0) 0.13
 Cancer 7 (11.9) 3 (9.1) 0.68
Nursing-home resident (n (%)) 2 (3.3) 0 (0.0) 0.29
Main admission diagnosis    
 Respiratory distress (n (%)) 21 (35.0) 12 (36.3) 0.89
 Extrapulmonary sepsis (n (%)) 19 (31.7) 14 (42.4) 0.30
 Neurologic failure (n (%)) 6 (10.0) 4 (12.1) 0.75
 Abdominal surgery (n (%)) 2 (3.3) 0 (0.0) 0.29
 Miscellaneous (n (%)) 12 (20.0) 3 (9.1) 0.17
Nasogastric tube (Yes (%)) 58 (96.7) 33 (100) 0.30
CPIS day-1 5.0 (2.0-9.0) 5.0 (3.0-8.0) 0.38
CPIS day-3 7.0 (5.0-11.0) 7.0 (5.0-10.0) 0.30
SOFA day-1 7.0 (4.0-15.0) 10.0 (5.0-16.0) <0.01
SOFA day-3 7.0 (4.0-14.0) 8.0 (4.0-15.0) 0.08
Renal failure on admission (Yes (%)) 30 (50.0) 20 (60.6) 0.33
Serum creatinine (VAP day-1) 90.0 (27.0-404.0) 137.0 (34.0-321.0) 0.02
Serum creatinine (VAP day-3) 84.0 (14.0-332.0) 111.0 (27.0-329.0) 0.20
Length of ICU stay until VAP (days) 10.0 (2.0-60.0) 10.0 (2.0-72.0) 0.90
Duration of MV until VAP (days) 12.0 (2.0-52.0) 7.0 (2.0-69.0) 0.44
Septic shock (VAP day-1) (n (%)) 18 (30.5) 17 (51.5) 0.05
Late-onset VAP (≥5 days after MV onset) (n (%)) 41 (68.3) 25 (75.8) 0.45
MDR bacteria (n (%)) 19 (32.2) 14 (42.4) 0.33
Appropriate antibiotic therapy within the first 24-hour of VAP (n (%)) 49 (83.0) 21 (65.6) 0.06
Steroids therapy during VAP period (n (%)) 23 (39.6) 18 (54.5) 0.17
Statin continuation after ICU admission (n (%)) 37 (61.7) 15 (45.4) 0.13
  1. VAP, ventilator-associated pneumonia; SAPS II, simplified acute physiology score II; ICU, intensive care unit; COPD, chronic obstructive pulmonary disease; CPIS, clinical pulmonary infection score; SOFA, sequential organ failure assessment; MV, mechanical ventilation; MDR, multidrug resistant.